Stocks Health care CYTK

NASDAQ · Health care

Cytokinetics Inc (CYTK)

Cytokinetics Inc brought in $67.7M of revenue over the twelve months to June 30, 2026, down 21.1% from a year earlier. It posted a net loss of $894M. In fiscal 2025 capital spending exceeded operating cash flow by $534.8M. At June 30, 2026 it held $255.3M in cash against $275.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

What Cytokinetics Inc does

Cytokinetics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CYTK.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Where CYTK ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Cytokinetics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 28, 2026
   Other event 8-K
2. August 13, 2026
   Passive stake changed SCHEDULE 13G/A
3. August 13, 2026
   Other event 8-K
4. August 6, 2026
   Quarterly report 10-Q · period to June 30, 2026
5. August 6, 2026
   Quarterly results 8-K
6. July 8, 2026
   Passive stake changed SCHEDULE 13G/A
7. May 27, 2026
   Employee stock plan registration S-8
8. May 27, 2026
   Shareholder vote results 8-K
9. May 8, 2026
   Other event 8-K
10. May 7, 2026
    Securities offering prospectus 424B5

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 22, 2026. Insider transactions on SEC

Insider trades

What the people running Cytokinetics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $9.6M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about CYTK

What does Cytokinetics Inc do?

Cytokinetics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CYTK.

Is Cytokinetics Inc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $894M on revenue of $67.7M.

How much revenue does Cytokinetics Inc make?

Over the twelve months to June 30, 2026 Cytokinetics Inc reported revenue of $67.7M. That is 21.1% less than a year earlier.

When did Cytokinetics Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 22, 2026.

Similar companies

Compare CYTK with

Compare CYTK with any company

Follow CYTK

Get an email when Cytokinetics Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow CYTK: get an email when it files

Where the numbers come from

Financial figures are the values Cytokinetics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.